This article was originally published in The Gray Sheet
Executive SummaryTender offer begins for the company's outstanding warrants at an exercise price of $7 and outstanding rights to acquire such warrants at $0.25 per warrant, net to seller. "Encore is making the tender offer to eliminate the potential dilutive effect that would occur if the warrants or rights to the warrants were exercised by the holders thereof on or before March 25, 2001," the firm explains. About 1.2 mil. warrants and 445,220 purchase rights are outstanding. The tender offer will remain open through Dec. 30
You may also be interested in...
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.